Mohamed Allaf: Aspirin and Clopidogrel Show Comparable Long-Term Survival After TAVI
Mohamed Allaf, Associate College Tutor at Royal College of Physician, Director of Specialtyapp, Internal Medicine Residency at NHS England, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in adding:
“To the best of our knowledge, this is the largest study comparing aspirin versus clopidogrel following TAVI.
Our analysis showed comparable long-term survival in patients treated with either aspirin or clopidogrel.
Further randomized trials are required for the validation of our results.”
Title: Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis
Article: Anastasios Apostolos, Konstantinos Konstantinou, Mohammed Allaf, Athanasios Sakalidis, Konstantinos Kalogeras, Ee Ling Heng, Simon Davies, Alison Duncan, Miles Dalby, Saeed Mirsadraee, Tarun Mittal, Aigul Baltabaeva, Tito Kabir, Mohammed Majid Akhtar, Robert Smith, Vasileios Panoulas
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM